SCHEMBL17329461

SCHEMBL17329461

CCCc1cc(O)c(CC=C(C)CCC=C(C)C)c(O)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.82
CNR1 P21554 2/20 0.82
CNR2 P34972 2/20 0.82
TRPV1 Q8NER1 2/20 0.82
SLC6A3 Q01959 2/20 0.82
TRPA1 O75762 1/20 0.82
INHA P05111 1/20 0.82
SLC6A2 P23975 1/20 0.82
HTR2A P28223 1/20 0.82
SLC6A4 P31645 1/20 0.82
OPRM1 P35372 1/20 0.82
KCNH2 Q12809 1/20 0.82
TRPM8 Q7Z2W7 1/20 0.82
TRPV3 Q8NET8 1/20 0.82
TRPV4 Q9HBA0 1/20 0.82
TRPV2 Q9Y5S1 1/20 0.82
PTPN1 P18031 1/20 0.67
BACE1 P56817 1/20 0.67
MAOB P27338 6/20 0.58
APP P05067 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6856702 1.00 PPARG (0.82) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL17345392 0.92 PPARG (0.70) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL23523476 0.92 PPARG (0.92) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL19422415 0.92 PPARG (0.92) PPARGCNR1CNR2TRPV1SLC6A3
Cannabigerol SCHEMBL144819 0.90 PPARG (1.00) PPARGCNR1CNR2TRPV1SLC6A3
Cannabigerol SCHEMBL14764730 0.90 PPARG (1.00) PPARGCNR1CNR2TRPV1SLC6A3
Cannabigerol SCHEMBL12954626 0.90 PPARG (1.00) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL23522969 0.89 PPARG (0.97) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL23523543 0.89 PPARG (0.97) PPARGCNR1CNR2TRPV1SLC6A3
SCHEMBL23523454 0.89 PPARG (0.97) PPARGCNR1CNR2TRPV1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021127559-A1 COMPOSITIONS COMPRISING CANNABINOID ANIONS AND ANTI-NUCLEATING AGENTS Natural Extraction Systems, LLC (US) 2021-06-24 WO claimed
WO-2021097150-A1 METHODS OF PREVENTING AND TREATING HEALTH CONDITIONS USING CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2021-05-20 WO claimed
WO-2021097163-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID ANIONS Natural Extraction Systems, LLC (US) 2021-05-20 WO claimed
WO-2021041637-A1 COMPOSITIONS COMPRISING CANNABINOID IONS DISSOLVING IN GLYCEROL Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
US-10807931-B2 Synthesis of phytocannabinoids including a decarboxylation step THE UNIVERSITY OF SYDNEY (AU) 2020-10-20 US claimed
US-20200172459-A1 SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP THE UNIVERSITY OF SYDNEY (AU) 2020-06-04 US claimed
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS NATURAL EXTRACTION SYS LLC (US) 2026-03-26 US disclosed
US-12484606-B2 Compositions and methods related to anionic cannabinoid molecules Natural Extraction Systems, LLC (US) 2025-12-02 US disclosed
EP-2961402-B1 BIOSYNTHESIS OF CANNABINOIDS TEEWINOT TECH LIMITED (IE) 2024-10-02 EP disclosed
US-20230190670-A1 COMPOSITIONS COMPRISING NOVEL CANNABINOID AND TERPENE PROFILES Natural Extraction Systems, LLC (US) 2023-06-22 US disclosed
US-20230172899-A1 CANNABINOID COMPOSITIONS THE QUEEN'S MEDICAL CENTER 2023-06-08 US disclosed
US-20230091336-A1 CANNABINOID COMPOSITIONS THE QUEEN'S MEDICAL CENTER 2023-03-23 US disclosed
US-20230059582-A1 CANNABINOID DERIVATIVES CANOPY GROWTH CORPORATION (CA) 2023-02-23 US disclosed
US-20160340629-A1 APPARATUS AND METHODS FOR BIOSYNTHETIC PRODUCTION OF CANNABINOIDS FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-11-24 US disclosed
US-20160264917-A1 APPARATUS AND METHODS FOR THE SIMULTANEOUS PRODUCTION OF COMPOUNDS FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-09-15 US disclosed
US-9394510-B2 Apparatus and methods for the simultaneous production of compounds FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-07-19 US disclosed
US-9359625-B2 Chemical engineering processes and apparatus for the synthesis of compounds FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-06-07 US disclosed
WO-2016030828-A1 APPARATUS AND METHODS FOR THE SIMULTANEOUS PRODUCTION OF CANNABINOID COMPOUNDS FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-03-03 WO disclosed
US-20160053220-A1 APPARATUS AND METHODS FOR THE SIMULTANEOUS PRODUCTION OF COMPOUNDS FULL SPECTRUM LABORATORIES LIMITED (IE) 2016-02-25 US disclosed
US-20150361469-A1 CHEMICAL ENGINEERING PROCESSES AND APPARATUS FOR THE SYNTHESIS OF COMPOUNDS FULL SPECTRUM LABORATORIES LIMITED (IE) 2015-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200172459-A1 SYNTHESIS OF PHYTOCANNABINOIDS INCLUDING A DECARBOXYLATION STEP CNR2, CNR1, CCNB1 PPARG 1757/4885CNR1 2/4885CNR2 1/4885
US-20230172899-A1 CANNABINOID COMPOSITIONS CNR2, CNR1, GPR18 PPARG 333/4885CNR1 2/4885CNR2 1/4885
US-20260083161-A1 CONTAINERS THAT CONTAIN ANIONIC CANNABINOIDS CNR2, CNR1, OPRD1 PPARG 966/4885CNR1 2/4885CNR2 1/4885
US-20230059582-A1 CANNABINOID DERIVATIVES CNR2, CNR1, GPR18 PPARG 137/4885CNR1 2/4885CNR2 1/4885
US-12484606-B2 Compositions and methods related to anionic cannabinoid molecules CNR2, CNR1, PHOSPHO1 PPARG 372/4885CNR1 2/4885CNR2 1/4885
US-20230091336-A1 CANNABINOID COMPOSITIONS CNR2, CNR1, GPR18 PPARG 255/4885CNR1 2/4885CNR2 1/4885
US-10807931-B2 Synthesis of phytocannabinoids including a decarboxylation step CNR2, CNR1, CCNB1 PPARG 1757/4885CNR1 2/4885CNR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.